CureVac and GSK entered into Pandemic preparedness contract with German government Candidate, CV2CoV

, , ,

On Apr. 11, 2022, CureVac and GSK announced that they had entered into a contract with the German federal government to supply mRNA vaccines within a broader tender for pandemic preparedness in Germany.

Following a setup period of a maximum of two years, the contract grants the German federal government access to CureVac’s manufacturing capacity until 2029, enabling rapid availability of 80 million mRNA-based vaccine doses during the remainder of the current pandemic or in future infectious disease outbreaks.

CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing, optimizing, and manufacturing this versatile biological molecule for medical purposes.

Tags:


Source: CureVac
Credit: